Mosaic ImmunoEngineering, Inc. CPMV
0.06 USD 0.00 (+0.00%)
At closeNov 11, 2026, 4:00 PM EST
0.06 Day range 0.06
0.054 52-week range 0.868
- YTD
- -80.71%
- 1 year
- -93.09%
News
defenseworld.net Mosaic ImmunoEngineering (OTCMKTS:CPMV) Stock Jumps 432.8% – Here’s Why Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV - Get Free Report)'s stock price rose 432.8% during mid-day trading on Friday. The company traded as high as $0.3330 and last traded at $0.3330.…
defenseworld.net Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Short Interest Update Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 31st, there was short interest totaling…
accesswire.com Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc. - The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy…
accesswire.com Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego - Nanoparticle-based technology complements the company's intratumoral technology platform - NOVATO, CA / ACCESSWIRE / October 6, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"),…
accesswire.com Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates NOVATO, CA / ACCESSWIRE / October 1, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and…
accesswire.com Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology - Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots - - Delivery system is transportation and storage friendly…
accesswire.com Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studies Epitopes used in the vaccine candidates are located in regions that…
accesswire.com Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego - Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications - - Data Supporting the Potential of Lead Vaccine…
accesswire.com Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Immunotherapy Candidate, MIE-101 - Results Demonstrate Innate Immune System Activation Through Stimulation of Three Toll-Like Receptors (TLRs 2,4,7) - - MIE-101 Therapy Reduced Tumor Growth by 80% Compared to Tumors Treated with…
accesswire.com Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused onimmunotherapies to treat and…